- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Aligos Therapeutics Inc (ALGS)
Aligos Therapeutics Inc stock price live, this page displays NASDAQ ALGS stock exchange data. View the ALGS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Aligos Therapeutics Inc real time stock price chart below.
What Is the Aligos Therapeutics Inc Stock Price Today?
The Aligos Therapeutics Inc stock price today is 7.690.
What Is the Stock Symbol for Aligos Therapeutics Inc?
The stock symbol for Aligos Therapeutics Inc is ""ALGS.""
What Stock Exchange Does Aligos Therapeutics Inc Trade On?
Aligos Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Aligos Therapeutics Inc a Good Stock to Buy?
Determining whether Aligos Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ALGS quote. (ISIN: US01626L2043)
What Is the Aligos Therapeutics Inc Stock Price Today?
The Aligos Therapeutics Inc stock price today is 7.690.
What Is the Stock Symbol for Aligos Therapeutics Inc?
The stock symbol for Aligos Therapeutics Inc is ""ALGS.""
What Stock Exchange Does Aligos Therapeutics Inc Trade On?
Aligos Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Aligos Therapeutics Inc a Good Stock to Buy?
Determining whether Aligos Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ALGS quote. (ISIN: US01626L2043)
7.690
-0.440(-5.41%)
Closed·
After Hours
7.6900.000(0.00%)
·
Fair Value
An estimate of a Aligos's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.540
8.490
52 wk Range
3.760
46.800
ALGS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
ALGS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Aligos's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.5408.490
52 wk Range
3.76046.800
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ALGS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Aligos's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
90.333
Upside
+1,074.69%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Aligos Therapeutics Inc Company Profile
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Compare ALGS to Peers and Sector
Metrics to compare | ALGS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALGSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.6x | −1.5x | −0.5x | |
PEG Ratio | −0.03 | −0.03 | 0.00 | |
Price/Book | 0.5x | 1.7x | 2.6x | |
Price / LTM Sales | 14.7x | 9.7x | 3.3x | |
Upside (Analyst Target) | - | 319.3% | 43.4% | |
Fair Value Upside | Unlock | 24.6% | 7.1% | Unlock |
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 90.333
(+1,074.69% Upside)
Earnings
Latest Release
May 06, 2025
EPS / Forecast
-2.11 / -0.18
Revenue / Forecast
311.00K / --
People Also Watch
FAQ
What Stock Exchange Does Aligos Trade On?
Aligos is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Aligos?
The stock symbol for Aligos is "ALGS."
What Is the Aligos Market Cap?
As of today, Aligos market cap is 47.24M.
What Is Aligos's Earnings Per Share (TTM)?
The Aligos EPS (TTM) is -9.47.
From a Technical Analysis Perspective, Is ALGS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Aligos Stock Split?
Aligos has split 1 times.
How Many Employees Does Aligos Have?
Aligos has 70 employees.
What is the current trading status of Aligos (ALGS)?
As of 08 Aug 2025, Aligos (ALGS) is trading at a price of 7.69, with a previous close of 8.13. The stock has fluctuated within a day range of 7.54 to 8.49, while its 52-week range spans from 3.76 to 46.80.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.